Abstract
In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Current Pharmaceutical Design
Title:Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations
Volume: 24 Issue: 28
Author(s): Linh Tran*
Affiliation:
- Computational Chemistry Research Group, Ton Duc Thang University, Ho Chi Minh, City,Vietnam
Keywords: Alzheimer's disease, Aβ species, conformational structure, Aβ inhibitors, computational approach, molecular simulations.
Abstract: In recent years, Aβ aggregation prevention, one of the most concerned strategies in drug development has been carefully assessed to treat Alzheimer’s disease. Aβ peptides can transform structurally from random coil monomer into β-stranded protofibril via multiple oligomeric states. Among the various Aβ species, the identification of binding targets has been challenging due to the heterogeneity and metastable nature. A better understanding of Aβ species’ assembly details and structural properties has been more characterized recently. Numerous potential inhibitors have been identified that they can effectively bind to different Aβ species such as monomer, oligomer or protofibril during the inhibition of Aβ aggregation process. This review highlights the diversity of structural ensembles of Aβ species, from monomer to protofibril forms and the specific binding targets by their potential inhibitors. Comprehending the binding mechanism of Aβ inhibitors is indispensable for searching novel drug candidates against early-stage Alzheimer’s disease.
Export Options
About this article
Cite this article as:
Tran Linh *, Understanding the Binding Mechanism of Amyloid-β Inhibitors from Molecular Simulations, Current Pharmaceutical Design 2018; 24 (28) . https://dx.doi.org/10.2174/1381612824666180813093420
DOI https://dx.doi.org/10.2174/1381612824666180813093420 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum β-Amyloid Peptide Levels Spike in the Early Stage of Alzheimer- Like Plaque Pathology in an APP/PS1 Double Transgenic Mouse Model
Current Alzheimer Research Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Commentary (Research Highlights: Targeted Inhibition of miR-155 Promotes Post-Stroke Neovascularization and Functional Recovery)
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Positron Emission Tomography (PET) in Medicinal Chemistry and Drug Discovery (Guest Editor: Ming-Rong Zhang)]
Current Topics in Medicinal Chemistry Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
Current Pharmaceutical Design Excitability of Dopamine Neurons: Modulation and Physiological Consequences
CNS & Neurological Disorders - Drug Targets Analgesic Drug Use Associated with Statin Prescription – A Cross- Sectional Study in Primary Care Settings
Current Drug Safety Pollen-Cross Allergenicity Mediated by Panallergens: A Clue to the Pathogenesis of Multiple Sensitizations
Inflammation & Allergy - Drug Targets (Discontinued) Mechanisms of MDMA (Ecstasy)-Induced Oxidative Stress, Mitochondrial Dysfunction, and Organ Damage
Current Pharmaceutical Biotechnology Application of Nanobioinformatics in Medical Science – A Probable Therapy
Current Bioinformatics Preface
Current Neuropharmacology Design and Synthesis of Tetrahydroisoquinoline Derivatives as Anti-Angiogenesis and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors
Current Medicinal Chemistry Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect
Current Drug Targets Meet Our Editorial Board Member:
Recent Patents on Inflammation & Allergy Drug Discovery Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Longitudinal Melatonin Production in Female Laboratory Rats During 1997-2006: Possible Modulatory Effects of Changing Solar Activity
Current Aging Science The Impact of Combinatorial Methodologies on Medicinal Chemistry
Current Topics in Medicinal Chemistry The Astrocytic GABAA/Benzodiazepine-Like Receptor: The Joker Receptor for Benzodiazepine-Mimetic Drugs?
Recent Patents on CNS Drug Discovery (Discontinued) Chemical Genomics and Emerging DNA Technologies in the Identification of Drug Mechanisms and Drug Targets
Current Topics in Medicinal Chemistry